These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 31387107)

  • 41. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
    Miftahussurur M; Shrestha PK; Subsomwong P; Sharma RP; Yamaoka Y
    BMC Microbiol; 2016 Nov; 16(1):256. PubMed ID: 27809767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of Helicobacter pylori.
    Fiorini G; Zullo A; Vakil N; Saracino IM; Ricci C; Castelli V; Gatta L; Vaira D
    J Clin Gastroenterol; 2018 Feb; 52(2):137-140. PubMed ID: 27136964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.
    Tong YF; Lv J; Ying LY; Xu F; Qin B; Chen MT; Meng F; Tu MY; Yang NM; Li YM; Zhang JZ
    World J Gastroenterol; 2015 Dec; 21(46):13073-9. PubMed ID: 26672777
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second-line rescue treatment of
    Lin TF; Hsu PI
    World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
    Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
    Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
    Prasertpetmanee S; Mahachai V; Vilaichone RK
    Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Helicobacter; 2016 Oct; 21(5):382-8. PubMed ID: 26809022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.
    Mansour-Ghanaei F; Joukar F; Naghipour MR; Forouhari A; Saadat SM
    World J Gastroenterol; 2015 Jan; 21(2):661-6. PubMed ID: 25593496
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
    Chen Q; Long X; Ji Y; Liang X; Li D; Gao H; Xu B; Liu M; Chen Y; Sun Y; Zhao Y; Xu G; Song Y; Yu L; Zhang W; Liu W; Graham DY; Lu H
    Aliment Pharmacol Ther; 2019 Jun; 49(11):1385-1394. PubMed ID: 31020673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
    Tepeš B; Vujasinović M; Šeruga M; Stefanovič M; Forte A; Jeverica S
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):676-83. PubMed ID: 26862930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan.
    Tai WC; Wu IT; Wang HM; Huang PY; Yao CC; Wu CK; Yang SC; Liang CM; Hsu PI; Chuah SK
    J Microbiol Immunol Infect; 2024 Aug; 57(4):601-608. PubMed ID: 38461114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
    Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
    Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate.
    Wu JY; Hsu PI; Wu DC; Graham DY; Wang WM
    Helicobacter; 2014 Jun; 19(3):207-13. PubMed ID: 24612093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication.
    De Francesco V; Ridola L; Hassan C; Bellesia A; Alvaro D; Vaira D; Zullo A
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):147-50. PubMed ID: 27308644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
    Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH
    P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.